Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

24 May 2017, Bangkok – This April and May, the targeted malaria elimination (TME) study in Laos’ final prevalence survey evaluated new tools to detect asymptomatic malaria. These included new rapid diagnostic tests (RDTs) that may be similar in sensitivity to a PCR performed on dried blood spots and reading machines that fire a laser at RDTs and use a thermal camera to detect faint positive results that would be beyond the range of the human eye.

Various researchers

Developed by Intellectual Ventures Laboratory with support from the Bill and Melinda Gates Foundation via Global Good, both are potential new malaria elimination tools as they could identify rapidly the asymptomatic reservoir of falciparum infections. Results are expected late summer 2017 comparing the new RDTs and readers to a gold standard method of malaria detection, the quantitative PCR results from Mallika Imwong’s molecular laboratory at MORU.

A team led by LOMWRU scientists Mayfong Mayxay and Koukeo Phommasone (bottom right), Tiengkham Pongvongsa (bottom centre), head of malaria control in Savannakhet Province, and WWARN’s Mehul Dhorda and MORU’s Lorenz von Seidlein and Tom Peto hosted Kevin Nichols and Stephen Burkhor (top left) of Intellectual Ventures Laboratory (IVL) to field test the tools.

Funded by the Bill and Melinda Gates Foundation, the MORU TME project seeks to accelerate malaria elimination by providing mass drug administrations (MDA) to communities that have relatively high P. falciparum prevalence, access to village health malaria workers and where every household has one or more long lasting insecticide treated bed nets. The TME project operates in four Greater Mekong Subregion countries: Myanmar, Cambodia, Laos and Viet Nam.

In Laos, the TME project focuses on rural villages in Savannakhet province, which has the third highest malaria incidence in Lao PDR. A survey conducted in 18 rural villages in Savannakhet in 2015 using uPCR detected Plasmodium infections in 175 of 888 samples (20%). Most villages in Savannakhet are relatively accessible and malaria elimination has a high priority for the local government. LOMWRU’s Dr Mayfong Mayxay is the principal investigator (PI) for the Lao PDR study, while Dr Koukeo Phommasone is the field site PI.

Similar stories

Risks of serious adverse events following treatment for visceral leishmaniasis

OCGHR Publication Research

This large-scale systematic review and meta-analysis aimed to collate all reported serious adverse events in visceral leishmaniasis clinical trials and quantify the incidence of mortality during the first 30 days of therapy. The analyses, which included clinical data from more than 35,000 patients, found that mortality following treatment was an extremely rare event and serious adverse events following treatments were poorly reported.

The RECOVERY Trial: One year on

OCGHR Research

The Randomised Evaluation of COVid-19 thERapY (RECOVERY) trial was officially launched on 23 March 2020. It is the world's largest COVID-19 drug trial. Thanks to the ground-breaking work of RECOVERY, clinicians treating patients hospitalised with severe COVID-19 now have two treatments that are known to improve survival.

Researchers call for access to Ivermectin for young children

OCGHR Publication Research

Millions of children weighing less than 15kg are currently denied access to Ivermectin treatment due to insufficient safety data being available to support a change to the current label indication. The WorldWide Antimalarial Resistance Network’s new meta-analysis provides evidence that supports removing this barrier and improving treatment equity.

Gender imbalance in visceral leishmaniasis clinical trials

OCGHR Publication Research

Researchers have found that despite an ongoing trend for a decreasing proportion of males being enrolled in antileishmanial therapeutic efficacy trials over time, there are still 1.8 times as many males as females involved in clinical trials. A new systematic review and meta-analysis suggests that existing knowledge on drug efficacy is derived from a study population that is heavily skewed towards adult males. At the same time, substantially less is known about the optimal treatment response in female patients.

New report highlights growing concern of vaccine falsification

MORU OCGHR

The Medicine Quality Research Group has published a new Medical Product Quality Report focussing on increasing issues around substandard and falsified (SF) COVID-19 vaccines. With the implementation of the key innovations of COVID-19 vaccines, there have been growing numbers of reports of SF vaccines in the public domain. Given the vital role they will play in ending the pandemic and protecting the global population but severe issues with equitable access, SF vaccines are highly likely to be a growing problem.

RECOVERY trial closes recruitment to colchicine treatment for patients hospitalised with COVID-19

OCGHR Research

Established to test a range of potential treatments for COVID-19, the RECOVERY trial has included a comparison of colchicine, an anti-inflammatory drug that is commonly used to treat gout, vs. usual care alone. There has been no convincing evidence of the effect of colchicine on clinical outcomes in patients admitted to hospital with COVID-19, and recruitment to the colchicine arm of the RECOVERY trial has now closed. Recruitment to all other treatment arms – aspirin, baricitinib, Regeneron’s antibody cocktail, and dimethyl fumarate – continues as planned.